Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

Aytu Biopharma Q1 2026 Results: Net Loss of $3.88M

Aytu BioPharma reported significant warrant reclassifications from liability to equity following amendments in March 2026. The company maintains a $3.8 million Employee Retention Credit accrual and continues to manage debt through an Eclipse Business Capital loan agreement, while focusing on its ADHD and Pediatric portfolios.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Revenue14.813.9
Gross profit9.49.2
Profit before tax-3.92.0
Net income-3.92.0
EPS (diluted, $ a share)$-0.20$-0.08

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+6.9%
Gross margin63.6%
Operating margin-26.5%
Source

10-Q filed with the SEC, NASDAQ: AYTU. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Aytu Biopharma, Inc: key numbers

Share price
$1.82Close, Nov 16
Market cap
$19.8M
Shares outstanding
10.87MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Aytu Biopharma, Inc

All →
4:28 PM ET 8-K
M&A Deal

Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.

Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.

“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”

Josh Disbrow, Chief Executive Officer of Aytu

“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”

Josh Disbrow, Chief Executive Officer of Aytu
4:09 PM ET 8-K
M&A Deal

Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.

Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.

Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
4:07 PM ET 8-K
Financial Results

Aytu Biopharma Financial Results

Aytu BioPharma reported fiscal 2026 fourth quarter net revenue of $16.1 million, a 6.4% increase year-over-year, driven by the commercial launch of EXXUA which generated $3.9 million in the quarter. For the full fiscal year 2026, net revenue was $57.6 million with a net loss of $14.3 million, as the company prioritized investments in its EXXUA launch over its legacy ADHD and pediatric portfolios.

Term
FY2026
Earnings call
Sep 22, 2026, 4:30 PM ET

“Although we remain in the early stages of the EXXUA launch, the continued momentum we saw throughout the fourth quarter further reinforces our confidence in this exciting opportunity.”

Josh Disbrow, Chief Executive Officer of Aytu

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.